N4P vs. MXC, RGT, CEL, CHLL, HELD, HLN, HIK, HCM, INDV, and AMYT
Should you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), Chill Brands Group (CHLL), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), and Amryt Pharma (AMYT). These companies are all part of the "drug manufacturers - specialty & generic" industry.
N4 Pharma vs. Its Competitors
Argent BioPharma (LON:MXC) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.
Argent BioPharma has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, indicating that its stock price is 137% less volatile than the S&P 500.
In the previous week, N4 Pharma had 1 more articles in the media than Argent BioPharma. MarketBeat recorded 2 mentions for N4 Pharma and 1 mentions for Argent BioPharma. Argent BioPharma's average media sentiment score of 0.76 beat N4 Pharma's score of 0.37 indicating that Argent BioPharma is being referred to more favorably in the media.
Argent BioPharma has a net margin of 0.00% compared to N4 Pharma's net margin of -18,399.86%. Argent BioPharma's return on equity of 0.00% beat N4 Pharma's return on equity.
1.2% of Argent BioPharma shares are owned by institutional investors. Comparatively, 0.2% of N4 Pharma shares are owned by institutional investors. 8.2% of Argent BioPharma shares are owned by company insiders. Comparatively, 22.0% of N4 Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
N4 Pharma has lower revenue, but higher earnings than Argent BioPharma. N4 Pharma is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
Argent BioPharma beats N4 Pharma on 7 of the 12 factors compared between the two stocks.
Get N4 Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding N4P and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
N4 Pharma Competitors List
Related Companies and Tools
This page (LON:N4P) was last updated on 9/7/2025 by MarketBeat.com Staff
Free N4P Stock Alerts